Endometrial Carcinoma

Ellenson, Lora Hedrick; Ronnett, Brigitte M.; Soslow, Robert A.; Zaino, Richard J.; Kurman, Robert J.

doi:10.1007/978-1-4419-0489-8_9

Cited by 29 publications

(32 citation statements)

References 389 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mass screening of the population for EC is not practical and no blood test with sufficient sensitivity and specificity has been developed (1,2). Screening for EC or its precursors is justified for certain high-risk populations, such as postmenopausal women on exogenous estrogens without progestins, women from families with Lynch syndrome and premenopausal women with anovulatory cycles such as those with polycystic ovarian disease (2).…”

Section: Discussionmentioning

confidence: 99%

“…Worldwide, ∼150 000 cases are diagnosed each year, making EC the fifth most common cancer in women (1). Although the highest rates of EC are seen in Europe and North America, reports from many other countries have shown an increased incidence of EC .…”

Section: Introductionmentioning

confidence: 99%

“…Although the highest rates of EC are seen in Europe and North America, reports from many other countries have shown an increased incidence of EC . While the incidence rates in developing countries and Japan are four to five times lower (1), the age-adjusted incidence rate of EC in Japan has been increasing since the 1970s.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hypertriglyceridemia is Frequent in Endometrial Cancer Survivors

Hirasawa

Makita

Akahane

et al. 2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

ObjectivePrevious studies have reported an association between endometrial cancer and the risk of metabolic syndrome; however, the pattern of endometrial cancer-associated dyslipidemia is not well understood. The standard therapy for endometrial cancer is total abdominal hysterectomy and bilateral salpingo-oophorectomy. Premenopausal bilateral salpingo-oophorectomy may cause adverse events, including dyslipidemia. Gynecologists have to care dyslipidemia in endometrial cancer survivors at cancer follow-up clinic.MethodsThis study included 693 patients who had undergone bilateral salpingo-oophorectomy, and included 412 women with incident endometrial cancer and 281 controls. We divided the patients into two categories according to whether they had a premenopausal or postmenopausal bilateral oophorectomy. Serum lipid levels were measured and statistically analyzed.ResultsHypertriglyceridemia was statistically more frequent in patients who had undergone bilateral salpingo-oophorectomy both before and after menopause than in the corresponding non-endometrial cancer controls. High levels of low-density lipoprotein cholesterol and a high low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio were statistically more frequent in patients who had undergone bilateral salpingo-oophorectomy before menopause than in non-endometrial cancer controls.ConclusionsOur report highlights the importance of the relationship between endometrial cancer and lipid metabolism, which may aid in preventing cerebrovascular or cardiovascular diseases due to dyslipidemia and improving the quality of life in endometrial cancer survivors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hypertriglyceridemia is Frequent in Endometrial Cancer Survivors

Hirasawa

Makita

Akahane

et al. 2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Uterine carcinoma is the most common gynecologic cancer in developed countries and is traditionally classified as two major types [1,2]. Approximately 80% of uterine carcinomas belong to the Type I category, comprising endometrioid carcinoma, and the remaining 20% belong to the Type II carcinomas, which are mainly composed of serous carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Laminin C1 expression by uterine carcinoma cells is associated with tumor progression

Kashima

Wang

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

Objectives Molecular markers associated with tumor progression in uterine carcinoma are poorly defined. In this study, we determine whether upregulation of LAMC1, a gene encoding extracellular matrix protein, laminin γ1, is associated with various uterine carcinoma subtypes and stages of tumor progression. Methods An analysis of the immunostaining patterns of laminin γ1 in normal endometrium, atypical hyperplasia, and a total of 150 uterine carcinomas, including low-grade and high-grade endometrioid carcinomas, uterine serous and clear cell carcinoma, was performed. Clinicopathological correlation was performed to determine biological significance. The Cancer Genome Atlas (TCGA) data set was used to validate our results. Results As compared to normal proliferative and secretory endometrium, for which laminin γ1 immunore-activity was almost undetectable, increasing laminin C1 staining intensity was observed in epithelial cells from atypical hyperplasia to low-grade endometrioid to high-grade endometrioid carcinoma, respectively. Laminin γ1 expression was significantly associated with FIGO stage, myometrial invasion, cervical/adnexal involvement, angiolymphatic invasion and lymph node metastasis. Similarly, analysis of the endometrial carcinoma data set from TCGA revealed that LAMC1 transcript levels were higher in high-grade than those in low-grade endometrioid carcinoma. Silencing IAMC1 expression by siRNAs in a high-grade endometrioid carcinoma cell line did not affect its proliferative activity but significantly suppressed cell motility and invasion in vitro. Conclusions These data suggest that laminin γ1 may contribute to the development and progression of uterine carcinoma, likely through enhancing tumor cell motility and invasion. Laminin γ1 warrants further investigation regarding its role as a biomarker and therapeutic target in uterine carcinoma

show abstract

“…Malignant mixed Mullerian tumours (MMMTs), or carcinosarcomas, account for <5% of the malignant neoplasms involving the uterine corpus 1. Owing to low prevalence, the risk factors for MMMT have been difficult to determine.…”

Section: Introductionmentioning

confidence: 99%

Malignant mixed Mullerian tumour of uterus secondary to tamoxifen therapy for hormone responsive breast cancer

Gupta

Kiruthiga

2015

BMJ Case Reports

View full text Add to dashboard Cite

Tamoxifen is used in the treatment of hormone responsive breast cancer because of its antiestrogenic effect. However, it also has an estrogenic effect on the uterus, thereby increasing the risk of endometrial hyperplasia, endometrial polyp and endometrial neoplasms such as endometrial adenocarcinoma and malignant mixed Mullerian tumour (MMMT). This case describes the possible pathogenesis and risk of developing MMMT due to long-term tamoxifen intake in hormone responsive breast cancer.

show abstract

Endometrial Carcinoma

Cited by 29 publications

References 389 publications

Hypertriglyceridemia is Frequent in Endometrial Cancer Survivors

Hypertriglyceridemia is Frequent in Endometrial Cancer Survivors

Laminin C1 expression by uterine carcinoma cells is associated with tumor progression

Malignant mixed Mullerian tumour of uterus secondary to tamoxifen therapy for hormone responsive breast cancer

Contact Info

Product

Resources

About